05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
16:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Nov. 14 decision that invalidated second medical use patent...
23:32 , Nov 14, 2018 |  BC Extra  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Wednesday decision that invalidated second medical use patent claims...
01:12 , Jun 16, 2018 |  BioCentury  |  Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and...
20:49 , Feb 16, 2018 |  BC Week In Review  |  Company News

Teva, Allergan settle working capital dispute

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said Allergan plc (NYSE:AGN) agreed to pay Teva $700 million to settle a dispute that arose after Teva purchased Allergan's global generic pharmaceuticals business. In November 2017, Teva...
21:02 , Jan 26, 2018 |  BC Week In Review  |  Company News

BIA intervenes on plausibility in patent law in Supreme Court case

The U.K. Bioindustry Association said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert Company LLC v. Generics UK Ltd and Actavis to examine the issue of plausibility in...
21:38 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Oculis raises CHF20M series B

Oculis S.A. (Lausanne, Switzerland) raised CHF20 million ($20.3 million) on Jan. 4 in a tranched series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners with participation by existing investors...
08:02 , Jan 4, 2018 |  BC Extra  |  Financial News

Oculis raises CHF20M series B

Oculis ehf (Lausanne, Switzerland) raised CHF20 million ($20.3 million) in a series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors Brunnur Ventures and Silfurberg also participated. The...
21:20 , Nov 9, 2017 |  BC Innovations  |  Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...